NK Cells Plus ICI for SCLC Maintenance
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This research study is designed for patients with extensive-stage small cell lung cancer (ES-SCLC) who have already received four cycles of standard chemotherapy, with at least two cycles combined with immunotherapy, and have achieved disease control (stable disease, partial response, or complete response) at their last efficacy evaluation. In this study, participants will be randomly assigned to one of two groups: Group A will receive standard immunotherapy plus 1 to 3 courses of allogeneic natural killer (NK) cell therapy. Each course consists of six NK cell infusions given over 28 days. Group B will receive standard immunotherapy alone. All participants will continue treatment until their disease progresses or they experience unacceptable side effects. The immunotherapy agents used in this study are those recommended by major international and national clinical guidelines for extensive-stage SCLC, including but not limited to durvalumab, atezolizumab, serplulimab, and adebrelimab. The purpose of this study is to evaluate whether adding NK cell therapy to standard immunotherapy can provide additional benefits for patients with extensive-stage SCLC who have responded well to initial treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Zaawansowany rak płuca drobnokomórkowy potwierdzony badaniem histologicznym
- •Ukończone 4 cykle chemioterapii, w tym co najmniej 2 cykle z immunoterapią, z dobrą odpowiedzią (ustabilizowanie choroby lub zmniejszenie nowotworu)
- •Widoczne ogniska choroby, które można zmierzyć badaniami obrazowymi
- •Przewidywany czas przeżycia co najmniej 1 rok
- •Prawidłowe wyniki badań morfologii krwi, wątroby i nerek
- •Brak chorób autoimmunologicznych
- •Dobra ogólna kondycja zdrowotna (ECOG 0-2)
✗ Disqualifies
- •Uczestnictwo w innym badaniu klinicznym lub stosowanie innego leku badawczego
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Tianjin First Central Hospital
Tianjin, China
Trial contact
Gang Zhi Zhao
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.